Beta Bionics, Inc. BBNX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -83.12M | -72.97M | -66.44M | -73.20M | -77.84M |
| Total Depreciation and Amortization | 4.35M | 3.72M | 3.26M | 2.88M | 2.47M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 24.18M | 22.16M | 19.13M | 28.39M | 29.33M |
| Change in Net Operating Assets | -4.78M | -8.72M | -10.73M | -8.99M | -10.53M |
| Cash from Operations | -59.37M | -55.81M | -54.78M | -50.93M | -56.58M |
| Capital Expenditure | -6.59M | -5.60M | -6.34M | -5.30M | -3.96M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -58.06M | 64.52M | 44.50M | -157.51M | -189.17M |
| Cash from Investing | -64.65M | 58.92M | 38.16M | -162.81M | -193.13M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 167.08M | 6.14M | 4.38M | 214.87M | 213.85M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | 59.66M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -2.81M |
| Cash from Financing | 167.08M | 6.14M | 4.38M | 214.87M | 270.71M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 43.07M | 9.24M | -12.25M | 1.14M | 21.00M |